Form 4: Blueprint Medicines CFO Michael Landsittel Sells Shares

Michael Landsittel, CFO of Blueprint Medicines Corp, sold 4,409 shares of common stock on August 15, 2024, at a weighted average price of $95.23 per share.

Summary

• On August 15, 2024, Michael Landsittel, the Chief Financial Officer of Blueprint Medicines Corp, sold 4,409 shares of the company's common stock.
• The sale was executed at a weighted average price of $95.23 per share, with individual transactions ranging from $94.80 to $95.60.
• Following the transaction, Landsittel directly owns 67,208 shares of Blueprint Medicines Corp.
• The sale was conducted under a pre-arranged trading plan adopted on December 6, 2023, in accordance with Rule 10b5-1.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by a company executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Insider sales are a common occurrence in publicly traded companies. They are often scrutinized by investors as they can provide insights into management's perspective on the company's future prospects. However, sales under pre-arranged trading plans are generally viewed as less informative, as they are often implemented for personal financial planning reasons.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.

Key Dates